Thermo Fisher ScientificvsTurn Therapeutics

TMO and TTRX stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$669.54

Value $249B

-2.79%
TMO's page

TTRX

Turn Therapeutics Inc.

$8.10

Value $241M

-6.31%
TTRX's page

Thermo Fisher Scientific (TMO) has a market value of $249B and Turn Therapeutics (TTRX) $241M. Over the last year, with dividends, TMO moved +17.1% and TTRX +186.2%. Dividend yield: TMO 0.27%, TTRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TMO$249B

    TTRX$241M

    TMO is 1,031 times TTRX

  • Revenue, 12 months

    TMO$47.4B

    TTRX–

  • Net income, 12 months

    TMO$7.1B

    TTRX-$13M

  • Operating margin

    TMO17.9%

    TTRX–

  • ROIC

    TMO8.2%

    TTRX–

  • P/E

    TMO35.2

    TTRX–

  • Dividend yield

    TMO0.3%

    TTRX0.0%

    0.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TMO+17.1%

TTRX+186.2%

200400DecFebAprJunAugOct
Returns by period
PeriodTMOWith dividendsTTRXWith dividends
1 year since November 19, 2025+17.1%Price +16.7%+186.2%Price +186.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TMOThermo Fisher ScientificTTRXTurn Therapeutics

Valuation

TMOTTRX
Valuation
Price$669.54$8.10
Market value$249B$241M
Enterprise value (EV)$284B$238M
P/E35.2–
P/E, 5-year median32.7–
P/B4.542.4
EV/EBIT33.5–
Free cash flow yield3.1%–

Results and growth

TMOTTRX
Results and growth
Revenue, 12 months$47.4B–
Net income, 12 months$7.1B-$13M
Free cash flow, 12 months$7.6B-$5.3M
Earnings per share, 12 months$18.96-$0.43
Revenue growth, year on year3.9%–
Revenue growth a year, past+6.7%over 5 years–
EPS growth a year, past+2.1%over 5 years–

Margins and returns on capital

TMOTTRX
Margins and returns on capital
Gross margin––
Operating margin17.9%–
Net margin14.9%–
ROIC8.2%–
ROE13.4%-361.1%

Balance sheet

TMOTTRX
Balance sheet
Cash$6.1B$9.4M
Total debt$41.4B$6.2M
Net debt / EBITDA3.7–
Interest cover5.5×–

Dividends and buybacks

TMOTTRX
Dividends and buybacks
Dividend yield0.3%–
Dividend per share, 12 months$1.84–
Dividend growth a year, past+14.3%over 5 years–
Buyback yield1.2%–
Shareholder yield1.5%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TMO or TTRX

Didn't find what you were looking for?

Ask us
Which is bigger, Thermo Fisher Scientific or Turn Therapeutics?

By market value, Thermo Fisher Scientific ($249B) is about 1,031.5 times Turn Therapeutics ($241M), at today's prices.

How did TMO and TTRX stock do over the last 1 years?

Since November 19, 2025, TMO's price moved +16.7% and TTRX's +186.2%. With dividends: TMO +17.1% (+17.1% a year), TTRX +186.2% (+186.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, TMO or TTRX?

The dividend yield at today's price is 0.27% for Thermo Fisher Scientific and none for Turn Therapeutics. Over the last twelve months they paid $1.84 and – per share.

Which is the better investment, Thermo Fisher Scientific or Turn Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.